<DOC>
	<DOCNO>NCT01685203</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy co-administration ABT-450 ( also know paritaprevir ) ritonavir ( ABT-450/r ) ABT-267 ( also know ombitasvir ) adult chronic hepatitis C virus infection .</brief_summary>
	<brief_title>A Study Evaluate Safety Effect Co-administration ABT-450 With Ritonavir ( ABT-450/r ) ABT-267 Adults With Chronic Hepatitis C Virus Infection</brief_title>
	<detailed_description>This Phase 2 , randomize , open-label , combination treatment study 2-DAA regimen ( ABT-450 150 mg QD + ritonavir 100 mg QD + ABT-267 25 mg QD ) adult HCV GT1b-infected treatment-naïve Pegylated-interferon/ribavirin ( pegIFN/RBV ) treatment-experienced participant without cirrhosis compensate cirrhosis , adult GT4-infected treatment-naïve pegIFN/RBV treatment-experienced participant without cirrhosis . Treatment Group 5 open enrollment , base protocol-specified interim review result treatment-naïve GT4 Groups 1 4 indicate high sustain virologic response ( SVR ) rate among participant receive 2-DAA regimen RBV . All group complete study .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<criteria>Females must practice specific form birth control study treatment , postmenopausal 2 year surgically sterile Subjects must meet one follow : Treatmentnaive : Subject never receive antiviral treatment hepatitis C infection OR Treatment Experienced ( Prior null responder , Partial responder Relapsers pegIFN/RBV ) ; Body mass index ( BMI ) ≥ 18 &lt; 38 kg/m^2 . Chronic HCV genotype 1b infection/with without cirrhosis HCV genotype 4 infection/without cirrhosis least 6 month prior study screen . Subject plasma HCV RNA level &gt; 10,000 IU/mL Screening History severe , lifethreatening significant sensitivity drug . Females pregnant plan become pregnant , breastfeeding , GT4infected male whose partner pregnant plan become pregnant within 7 month ( per local RBV label ) last dose study drug/RBV . Recent history drug alcohol abuse could preclude adherence protocol . Positive test result hepatitis B surface antigen antiHuman Immunodeficiency Virus ( HIV ) antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Hepatitis C Virus</keyword>
	<keyword>Ribavirin-Free</keyword>
	<keyword>Hepatitis C Genotype 1</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Interferon-Free</keyword>
	<keyword>Chronic Hepatitis C</keyword>
	<keyword>Compensated cirrhosis</keyword>
	<keyword>Hepatitis C Genotype 4</keyword>
	<keyword>Paritaprevir</keyword>
	<keyword>Ombitasvir</keyword>
	<keyword>Ritonavir</keyword>
	<keyword>Ribavirin</keyword>
</DOC>